Pediatric Atopic Dermatitis: Treatment Selection Considerations During the COVID-19 Pandemic
Friday, August 12, 2022
7:30 AM – 9:00 AM ET
6:30 AM – 8:00 AM CT
5:30 AM – 7:00 AM MT
4:30 AM – 6:00 AM PT
After participating in this educational initiative, clinicians should be better able to:
- Assess the benefits and risks of using systemic immunosuppressants and immunomodulators during the COVID-19 pandemic
- Evaluate clinical trial data on the efficacy and safety of systemic therapies for the management of moderate-to-severe atopic dermatitis in children and adolescents
- Develop personalized treatment plans that address disease severity, patient-specific factors, and quality of life in children and adolescents with atopic dermatitis.
This activity is intended for pediatricians, dermatologists, pediatric dermatologists, primary care physicians, and other healthcare professionals involved in the management of pediatric and adolescent patients with atopic dermatitis.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation Statement
Med Learning Group designates this live activity for a maximum of 1.50 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis. CNE Credits : 1.50 ANCC Contact Hour(s).
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.Awarded 1.50 contact hours of continuing nursing education of RNs and APNs.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
Release date: August 12, 2022
Expiration date: August 12, 2023
Estimated time to completion: 1.5 hours